Article
Pruritus in primary myelofibrosis: clinical and laboratory correlates.
American journal of hematology - 1 Feb 2012
Vaa Brianna E, Wolanskyj Alexandra P, Roeker Lindsey, Pardanani Animesh, Lasho Terra L, Finke Christy M, Tefferi Ayalew
Abstract excerpt
Recent clinical trials with JAK or mammalian target of rapamycin (mTOR) inhibitors in primary myelofibrosis (PMF) have identified pruritus as one of the most treatment-responsive disease traits. However, little is known about the prevalence of pruritus in PMF or its clinical and laboratory correlates. Among 566 consecutive patients with PMF seen at our institution, the presence or absence of pruritus was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.